-
Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer
- 2024/08/07
- 再生時間: 1 時間 15 分
- ポッドキャスト
-
サマリー
activate_samplebutton_t1
あらすじ・解説
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.